Mural Oncology (NASDAQ:MURA) Earns Overweight Rating from Analysts at Morgan Stanley

Equities researchers at Morgan Stanley began coverage on shares of Mural Oncology (NASDAQ:MURA) in a research note issued on Thursday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $13.00 price target on the stock. Morgan Stanley’s target price would suggest a potential upside of 200.23% from the company’s current price.

Mural Oncology Trading Down 5.9 %

MURA opened at $4.33 on Thursday. Mural Oncology has a 52 week low of $3.23 and a 52 week high of $17.00. The company has a fifty day moving average price of $4.80.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.